Embla Medical hf. (OSSUY)
OTCMKTS · Delayed Price · Currency is USD
5.00
-0.61 (-10.87%)
At close: Feb 4, 2026
Embla Medical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 928.69 | 854.89 | 785.68 | 718.65 | 718.67 | |
Revenue Growth (YoY) | 8.63% | 8.81% | 9.33% | -0.00% | 14.16% |
Cost of Revenue | 350.13 | 320.19 | 300.11 | 278.9 | 263.28 |
Gross Profit | 578.56 | 534.7 | 485.57 | 439.75 | 455.39 |
Selling, General & Admin | 408 | 381.12 | 359.97 | 338.59 | 328.03 |
Research & Development | 45.86 | 40.83 | 38.14 | 34.02 | 31.74 |
Operating Expenses | 453.86 | 421.95 | 398.11 | 372.61 | 359.76 |
Operating Income | 124.7 | 112.75 | 87.46 | 67.14 | 95.62 |
Interest Expense | -19.52 | -23.25 | -17.96 | -11.2 | -9.8 |
Interest & Investment Income | 1.52 | 1.97 | 3.45 | 0.78 | 0.17 |
Earnings From Equity Investments | 6.66 | 3.34 | 3.4 | 0.36 | 0.4 |
Currency Exchange Gain (Loss) | -4.97 | -4.44 | -0.67 | 2.61 | 1.12 |
Other Non Operating Income (Expenses) | -0.45 | 0.19 | 0.33 | -3.51 | -0.87 |
EBT Excluding Unusual Items | 107.94 | 90.56 | 76.01 | 56.17 | 86.64 |
Pretax Income | 107.94 | 90.56 | 76.01 | 56.17 | 86.64 |
Income Tax Expense | 24.29 | 21.6 | 17.21 | 12.96 | 20.98 |
Earnings From Continuing Operations | 83.65 | 68.96 | 58.8 | 43.21 | 65.66 |
Minority Interest in Earnings | -0.31 | -0.68 | -0.41 | -0.7 | -1.66 |
Net Income | 83.34 | 68.28 | 58.39 | 42.51 | 63.99 |
Net Income to Common | 83.34 | 68.28 | 58.39 | 42.51 | 63.99 |
Net Income Growth | 22.05% | 16.94% | 37.34% | -33.57% | 929.84% |
Shares Outstanding (Basic) | 427 | 427 | 420 | 418 | 422 |
Shares Outstanding (Diluted) | 427 | 427 | 420 | 418 | 423 |
Shares Change (YoY) | 0.08% | 1.51% | 0.60% | -1.17% | 0.02% |
EPS (Basic) | 0.20 | 0.16 | 0.14 | 0.10 | 0.15 |
EPS (Diluted) | 0.20 | 0.16 | 0.14 | 0.10 | 0.15 |
EPS Growth | 21.96% | 15.20% | 36.53% | -32.78% | 929.72% |
Free Cash Flow | 110.55 | 89.03 | 65.09 | 44.22 | 83.57 |
Free Cash Flow Per Share | 0.26 | 0.21 | 0.15 | 0.11 | 0.20 |
Gross Margin | 62.30% | 62.55% | 61.80% | 61.19% | 63.37% |
Operating Margin | 13.43% | 13.19% | 11.13% | 9.34% | 13.31% |
Profit Margin | 8.97% | 7.99% | 7.43% | 5.92% | 8.91% |
Free Cash Flow Margin | 11.90% | 10.42% | 8.29% | 6.15% | 11.63% |
EBITDA | 150.14 | 136.92 | 108.29 | 89.45 | 119.86 |
EBITDA Margin | 16.17% | 16.02% | 13.78% | 12.45% | 16.68% |
D&A For EBITDA | 25.45 | 24.16 | 20.83 | 22.31 | 24.23 |
EBIT | 124.7 | 112.75 | 87.46 | 67.14 | 95.62 |
EBIT Margin | 13.43% | 13.19% | 11.13% | 9.34% | 13.31% |
Effective Tax Rate | 22.50% | 23.85% | 22.64% | 23.08% | 24.22% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.